A cikin Maris 2017, FDA ta amince da ocrelizumab, wani anti-CD20 monoclonal antibody, a matsayin magani don RMS, tare da buƙatun don gwaji na Mataki na IV da yawa. A cikin RRMS suna da sauƙi a rage yawan hare-haren. Interferon beta-1a da interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, da cladribine. Ba a bayyana tasirin farashin su ba a cikin shekara ta 2012. A cikin Maris 2017, FDA ta amince da ocrelizumab, wani anti-CD20 monoclonal antibody, a matsayin magani don RMS, tare da buƙatun don gwaji na Mataki na IV da yawa. A cikin RRMS, suna da sauƙi a rage yawan hare-haren. Interferon beta-1a da glatiramer acetate sun kasance a farkon jerin abubuwan da suka faru, amma sun kasance a farkon jerin abubuwan da suka faru, amma sun kasance daidai da kashi 30 cikin dari.
interferon beta-1a